Claims for Patent: 8,642,608

Summary for Patent: 8,642,608

Title:	Quinazoline derivatives as VEGF inhibitors
Abstract:	The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R.sup.1 represents halogeno or C.sub.1-3alkyl; X.sup.1 represents --O--; R.sup.2 is selected from one of the following three groups: 1) C.sub.1-5alkylR.sup.3 (wherein R.sup.3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2) C.sub.2-5alkenylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); 3) C.sub.2-5alkynylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. ##STR00001##
Inventor(s):	Thomas; Andrew Peter (Macclesfield, GB), Stokes; Elaine Sophie Elizabeth (Macclesfield, GB), Hennequin; Laurent Francois Andre (Reims Cedex, FR)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	12/761,105
Patent Claims:	1. A method of inhibiting vascular endothelial growth factor (VEGF) receptor tyrosine kinase activity or endothelial growth factor (EGF) receptor tyrosine kinase activity in a warm-blooded animal suffering from a cancer associated with VEGF or EGF, comprising administering to said animal an effective amount of 4-(4-bromo-2-fluoroanilino)-6- methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline or a pharmaceutically acceptable salt thereof, wherein the cancer is a primary or recurrent solid tumor. 2. The method as claimed in claim 1, wherein the warm-blooded animal is a human. 3. The method as claimed in claim 1, wherein the solid tumor is significantly dependent on VEGF for its growth and/or spread. 4. The method as claimed in claim 1, wherein the solid tumor is significantly dependent on EGF for its growth and/or spread. 5. The method as claimed in claim 1, wherein the solid tumor is significantly dependent on VEGF and EGF for its growth and/or spread. 6. The method as claimed in claim 3, wherein the solid tumor which is significantly dependent on VEGF for its growth and spread is a tumor of the colon. 7. The method as claimed in claim 1, wherein the administering of the 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidine-4-ylmethoxy)q- uinazoline or a pharmaceutically acceptable salt thereof results in inhibition or slowing of the growth of the primary or recurrent solid tumor. 8. The method as claimed in claim 3, wherein the solid tumor which is significantly dependent on VEGF for its growth and spread is a tumor of the breast. 9. The method as claimed in claim 3, wherein the solid tumor which is significantly dependent on VEGF for its growth and spread is a tumor of the lung. 10. The method as claimed in claim 3, wherein the solid tumor which is significantly dependent on VEGF for its growth and spread is a tumor of the vulva. 11. The method as claimed in claim 3, wherein the solid tumor which is significantly dependent on VEGF for its growth and spread is a tumor of the skin.